



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1652
#23
AJ
RECEIVED

In re Application of
DAHLQUIST et al.
Serial No. 09/537,710
Filed: March 30, 2000

)
)
)
)
)
)
)

Art Unit: 1652

Examiner: Kerr

For: A NEW CLASS OF ENZYMES IN THE BIOSYNTHETIC PATHWAY FOR THE
PRODUCTION OF TRIACYLGLYCEROL AND RECOMBINANT DNA
MOLECULES ENCODING THESE ENZYMES

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Commissioner of Patents and Trademarks,
Washington, D.C. 20231, on:

April 8, 2003

Date of Deposit Herbert B. Keil

Person Making Deposit

Signature

April 8, 2003

Date of Signature

Honorable Comm'r. of Patents
Washington, D.C. 20231

REPLY TO RESTRICTION REQUIREMENT

Sir:

Applicants herein reply to the restriction requirement of March 10, 2003.

REMARKS

Provisional election with traverse:

Applicants elect with traverse SuperGroup F, Group I, and SEQ ID NOs: 1 and 2.

Argument:

Applicants believe the restriction requirement is improper.

To further aid the biotechnology industry in protecting its intellectual property without creating an undue burden on the Office, the Commissioner has decided *sua sponte* to partially waive the requirements of 37 CFR 1.141 *et seq.* and permit a reasonable number of such nucleotide sequences to be claimed in a single application. It has been determined that normally ten sequences constitute a reasonable number for examination purposes.